doi: 10.1021/acs.jmedchem.8b00315 23 ForcinaGCDixonSJ
Immunology and Allergy Clinics of North America
Easy dosing and portability
There is little agreement regarding the possible effects of insulin, with either no or an inhibitory effect on glucagon secretion [18], and variable effects on somatostatin secretion in some studies [18, 19], and no effect of insulin on somatostatin secretion in other studies [20]
Similar results are seen with another BET inhibitor, JQ1, suggesting that this family of proteins may be promising therapeutic targets (191)
Beyond pancreatic effects, GLP-1R agonists exert widespread extra-pancreatic benefits, attributed to the extensive distribution of GLP-1R in different organs, including gastrointestinal tract, kidneys, liver, skeletal and smooth muscle, neural tract, adipose tissue, and the cardiovascular system, where they are expressed in endothelial cells, vascular smooth muscle, cardiomyocytes, and different inflammatory cells [20], underpinning the synthetic GLP-1 and GLP-1RAs associated cardiovascular benefits observed in clinics [21]